People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Avenzoar Pharmaceuticals, Inc. | — | Biotechnology | Pre-Seed | $1.4M | $8.1M | 2023 |
Mark J. Chin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark J. Chin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Kramer | 1 | 7 |
| Shierley J. Widjaja | 1 | 1 |
| Stephen J. Pandol | 1 | 1 |
| Mouad J. Edderkaoui | 1 | 1 |
| Terrance J. Bruggeman | 1 | 1 |
| Terrance Bruggeman | 1 | 1 |
| Mouad Edderkaoui | 1 | 1 |
| William Reavey | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.